Last reviewed · How we verify

Morphine 6-glucuronide

Paion UK Ltd. · Phase 3 active Small molecule

Morphine 6-glucuronide is an active metabolite of morphine that binds to opioid receptors in the central nervous system to produce analgesia and other opioid effects.

Morphine 6-glucuronide is an active metabolite of morphine that binds to opioid receptors in the central nervous system to produce analgesia and other opioid effects. Used for Acute and chronic pain management, Postoperative pain.

At a glance

Generic nameMorphine 6-glucuronide
SponsorPaion UK Ltd.
Drug classOpioid receptor agonist
TargetMu-opioid receptor (μ-OR)
ModalitySmall molecule
Therapeutic areaPain Management
PhasePhase 3

Mechanism of action

Morphine 6-glucuronide (M6G) is formed through hepatic glucuronidation of morphine and acts as a mu-opioid receptor agonist. It crosses the blood-brain barrier and produces potent analgesic effects, potentially with a more favorable side effect profile than morphine itself. M6G accumulates in renal impairment, making it a consideration in pain management across different patient populations.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: